207 related articles for article (PubMed ID: 15766294)
21. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study.
Harfterkamp M; Buitelaar JK; Minderaa RB; van de Loo-Neus G; van der Gaag RJ; Hoekstra PJ
J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):194-9. PubMed ID: 23578015
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder.
Kaplan S; Heiligenstein J; West S; Busner J; Harder D; Dittmann R; Casat C; Wernicke JF
J Atten Disord; 2004 Oct; 8(2):45-52. PubMed ID: 15801334
[TBL] [Abstract][Full Text] [Related]
23. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.
Spencer T; Heiligenstein JH; Biederman J; Faries DE; Kratochvil CJ; Conners CK; Potter WZ
J Clin Psychiatry; 2002 Dec; 63(12):1140-7. PubMed ID: 12523874
[TBL] [Abstract][Full Text] [Related]
24. Effects of open-label atomoxetine on African-American and Caucasian pediatric outpatients with attention-deficit/hyperactivity disorder.
Durell TM; Pumariega AJ; Rothe EM; Tamayo JM; Baron D; Williams D
Ann Clin Psychiatry; 2009; 21(1):26-37. PubMed ID: 19239830
[TBL] [Abstract][Full Text] [Related]
25. Atomoxetine response in the inattentive and combined subtypes of attention deficit hyperactivity disorder: a retrospective chart review.
Ercan ES; Akyol Ardic U; Kabukcu Basay B; Ercan E; Basay O
Atten Defic Hyperact Disord; 2013 Dec; 5(4):377-85. PubMed ID: 23737214
[TBL] [Abstract][Full Text] [Related]
26. Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity.
Spencer TJ; Faraone SV; Michelson D; Adler LA; Reimherr FW; Glatt SJ; Biederman J
J Clin Psychiatry; 2006 Mar; 67(3):415-20. PubMed ID: 16649828
[TBL] [Abstract][Full Text] [Related]
27. Predictors of relapse or maintenance of response in pediatric and adult patients with attention-deficit/hyperactivity disorder following discontinuation of long-term treatment with atomoxetine.
Thome J; Dittmann RW; Greenhill LL; Lipsius S; Tanaka Y; Bushe C; Escobar R; Heinloth AN; Upadhyaya H
Atten Defic Hyperact Disord; 2017 Dec; 9(4):219-229. PubMed ID: 28477289
[TBL] [Abstract][Full Text] [Related]
28. Atomoxetine Increased Effect over Time in Adults with Attention-Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double-Blind, Placebo-Controlled, Randomized Trials.
Wietecha LA; Clemow DB; Buchanan AS; Young JL; Sarkis EH; Findling RL
CNS Neurosci Ther; 2016 Jul; 22(7):546-57. PubMed ID: 26922462
[TBL] [Abstract][Full Text] [Related]
29. Gender differences in 2 clinical trials of adults with attention-deficit/hyperactivity disorder: a retrospective data analysis.
Robison RJ; Reimherr FW; Marchant BK; Faraone SV; Adler LA; West SA
J Clin Psychiatry; 2008 Feb; 69(2):213-21. PubMed ID: 18211131
[TBL] [Abstract][Full Text] [Related]
30. Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment.
Spencer TJ; Kratochvil CJ; Sangal RB; Saylor KE; Bailey CE; Dunn DW; Geller DA; Casat CD; Lipetz RS; Jain R; Newcorn JH; Ruff DD; Feldman PD; Furr AJ; Allen AJ
J Child Adolesc Psychopharmacol; 2007 Oct; 17(5):689-700. PubMed ID: 17979588
[TBL] [Abstract][Full Text] [Related]
31. A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD).
Prasad S; Harpin V; Poole L; Zeitlin H; Jamdar S; Puvanendran K;
Curr Med Res Opin; 2007 Feb; 23(2):379-94. PubMed ID: 17288692
[TBL] [Abstract][Full Text] [Related]
32. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
[TBL] [Abstract][Full Text] [Related]
33. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
[TBL] [Abstract][Full Text] [Related]
34. Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia.
Martenyi F; Zavadenko NN; Jarkova NB; Yarosh AA; Soldatenkova VO; Bardenstein LM; Kozlova IA; Neznanov NG; Maslova OI; Petrukhin AS; Sukchotina NK; Zykov VP
Eur Child Adolesc Psychiatry; 2010 Jan; 19(1):57-66. PubMed ID: 19568826
[TBL] [Abstract][Full Text] [Related]
35. Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder.
Chang K; Nayar D; Howe M; Rana M
J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):547-51. PubMed ID: 19877979
[TBL] [Abstract][Full Text] [Related]
36. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.
Gau SS; Huang YS; Soong WT; Chou MC; Chou WJ; Shang CY; Tseng WL; Allen AJ; Lee P
J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):447-60. PubMed ID: 17822340
[TBL] [Abstract][Full Text] [Related]
37. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder.
Kratochvil CJ; Wilens TE; Greenhill LL; Gao H; Baker KD; Feldman PD; Gelowitz DL
J Am Acad Child Adolesc Psychiatry; 2006 Aug; 45(8):919-927. PubMed ID: 16865034
[TBL] [Abstract][Full Text] [Related]
38. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
[TBL] [Abstract][Full Text] [Related]
39. Validation of the adult attention-deficit/hyperactivity disorder quality-of-life scale in European patients: comparison with patients from the USA.
Brod M; Adler LA; Lipsius S; Tanaka Y; Heinloth AN; Upadhyaya H
Atten Defic Hyperact Disord; 2015 Jun; 7(2):141-50. PubMed ID: 25563210
[TBL] [Abstract][Full Text] [Related]
40. A randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy, safety, and tolerability of extended-release metadoxine in adults with attention-deficit/hyperactivity disorder.
Manor I; Ben-Hayun R; Aharon-Peretz J; Salomy D; Weizman A; Daniely Y; Megiddo D; Newcorn JH; Biederman J; Adler LA
J Clin Psychiatry; 2012 Dec; 73(12):1517-23. PubMed ID: 23290324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
